Vanguard Capital Management
CTKB icon

Vanguard Capital Management’s Cytek Biosciences CTKB Stock Holding History

Vanguard Capital Management’s Portfolio CTKB Stock Details CTKB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$21.9M Buy
4,939,597
+176,693
+4% +$754K ﹤0.01% 2400
2026
Q1 		$20.8M Buy
+4,762,904
New +$22.5M ﹤0.01% 2320

Other funds holding CTKB

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Boston Partners
Boston Partners Boston, Massachusetts $113B AUM 38.87% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $832M AUM 32.38% 1-Year Est. Return
TCM
Topline Capital Management Santa Monica, California $386M AUM 2.37% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
RA
Royce & Associates New York $12.4B AUM 64.17% 1-Year Est. Return

Vanguard Capital Management's CTKB Position: Q2 2026 in Review

Vanguard Capital Management increased its Cytek Biosciences (CTKB) stake by 3.7% in Q2 2026, buying an estimated $754K and bringing the position to 4,939,597 shares worth $21.9M. The position accounts for ﹤0.01% of the portfolio, ranked #2400.

Vanguard Capital Management first reported a position in CTKB in Q1 2026 and has held it in 2 quarters since. 154 funds tracked by Wall St. Rank hold CTKB as of Q2 2026.

  • Vanguard Capital Management held 4,939,597 shares of Cytek Biosciences worth $21.9M as of Q2 2026.
  • Vanguard Capital Management bought 176,693 Cytek Biosciences shares in Q2 2026, an estimated $754K.
  • Cytek Biosciences made up ﹤0.01% of Vanguard Capital Management's portfolio in Q2 2026, its #2400 holding.
  • Vanguard Capital Management first reported a position in Cytek Biosciences in Q1 2026 and has held it in 2 quarters since.
  • 154 funds tracked by Wall St. Rank held Cytek Biosciences as of Q2 2026.

Based on Vanguard Capital Management's 13F filing for Q2 2026, filed 13 Aug 2026.